As of 2025-06-02, the Fair Value of Karyopharm Therapeutics Inc (KPTI) is -94.45 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 4.20 USD, the upside of Karyopharm Therapeutics Inc is -2,348.79%.
With the market price of 4.20 USD and our fair value calculation, Karyopharm Therapeutics Inc (KPTI) is not a good investment. Investing in KPTI stocks now will result in a potential loss of 2,348.79%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -196.30 | -124.10 | -165.30 | -143.10 | -76.42 | -141.04 |
| YoY growth | 1.65% | 36.78% | -33.20% | 13.43% | 46.60% | 13.05% |
| Market Cap (mil) | 36.29 |
| P/E | |
| Forward P/E |
| EPS | -7.24 |
| Avg earnings growth rate | 13.05% |
| TTM earnings | -62.52 |